Willda 50 Tablet contains Vildagliptin 50 mg, an oral antihyperglycemic agent used in the management of type 2 diabetes mellitus. Vildagliptin belongs to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors, which work by enhancing the incretin system to regulate blood glucose levels. By inhibiting the DPP-4 enzyme, Vildagliptin increases the levels of active incretin hormones, such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), leading to increased insulin secretion and decreased glucagon release in a glucose-dependent manner. This dual action helps improve glycemic control without causing significant hypoglycemia. Willda 50 Tablet is typically prescribed as monotherapy or in combination with other antidiabetic agents, including metformin, when diet and exercise alone do not provide adequate glycemic control. It is important to administer this medication as directed by a healthcare professional, usually once or twice daily, with or without food. Patients should be monitored regularly for glycemic parameters and potential adverse effects, such as gastrointestinal disturbances or hypersensitivity reactions. Willda 50 Tablet is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, or known hypersensitivity to Vildagliptin or any excipients. Proper adherence to therapy, lifestyle modifications, and regular follow-up are essential for optimal diabetes management.